These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
190 related articles for article (PubMed ID: 8625321)
1. Identification of the lysyl oxidase gene as target of the antioncogenic transcription factor, IRF-1, and its possible role in tumor suppression. Tan RS; Taniguchi T; Harada H Cancer Res; 1996 May; 56(10):2417-21. PubMed ID: 8625321 [TBL] [Abstract][Full Text] [Related]
2. IRF-1 reverts the transformed phenotype of oncogenically transformed cells in vitro and in vivo. Kröger A; Dallügge A; Kirchhoff S; Hauser H Oncogene; 2003 Feb; 22(7):1045-56. PubMed ID: 12592391 [TBL] [Abstract][Full Text] [Related]
3. Transcription factor IRF-2 exerts its oncogenic phenotype through the DNA binding/transcription repression domain. Nguyen H; Mustafa A; Hiscott J; Lin R Oncogene; 1995 Aug; 11(3):537-44. PubMed ID: 7630638 [TBL] [Abstract][Full Text] [Related]
4. Cooperative activity between HER oncogenes and the tumor suppressor IRF-1 results in apoptosis. Kirchhoff S; Hauser H Oncogene; 1999 Jun; 18(25):3725-36. PubMed ID: 10391680 [TBL] [Abstract][Full Text] [Related]
9. Comparative functional study of the lysyl oxidase promoter in fibroblasts, Ras-transformed fibroblasts, myofibroblasts and smooth muscle cells. Reynaud C; Gleyzal C; Jourdan-Le Saux C; Sommer P Cell Mol Biol (Noisy-le-grand); 1999 Dec; 45(8):1237-47. PubMed ID: 10643973 [TBL] [Abstract][Full Text] [Related]
10. Targeted disruption of IRF-1 or IRF-2 results in abnormal type I IFN gene induction and aberrant lymphocyte development. Matsuyama T; Kimura T; Kitagawa M; Pfeffer K; Kawakami T; Watanabe N; Kündig TM; Amakawa R; Kishihara K; Wakeham A Cell; 1993 Oct; 75(1):83-97. PubMed ID: 8402903 [TBL] [Abstract][Full Text] [Related]
11. Tumour necrosis factor-alpha and interferon-gamma synergistically activate the RANTES promoter through nuclear factor kappaB and interferon regulatory factor 1 (IRF-1) transcription factors. Lee AH; Hong JH; Seo YS Biochem J; 2000 Aug; 350 Pt 1(Pt 1):131-8. PubMed ID: 10926836 [TBL] [Abstract][Full Text] [Related]
12. The role of the interferon regulatory factors, IRF-1 and IRF-2, in LPS-induced cyclooxygenase-2 (COX-2) expression in vivo and in vitro. Zhang S; Thomas K; Blanco JC; Salkowski CA; Vogel SN J Endotoxin Res; 2002; 8(5):379-88. PubMed ID: 12537697 [TBL] [Abstract][Full Text] [Related]
13. Negative modulation of alpha1(I) procollagen gene expression in human skin fibroblasts: transcriptional inhibition by interferon-gamma. Yuan W; Yufit T; Li L; Mori Y; Chen SJ; Varga J J Cell Physiol; 1999 Apr; 179(1):97-108. PubMed ID: 10082137 [TBL] [Abstract][Full Text] [Related]
14. IFN regulatory factor-1 gene transfer into an aggressive, nonimmunogenic sarcoma suppresses the malignant phenotype and enhances immunogenicity in syngeneic mice. Yim JH; Wu SJ; Casey MJ; Norton JA; Doherty GM J Immunol; 1997 Feb; 158(3):1284-92. PubMed ID: 9013971 [TBL] [Abstract][Full Text] [Related]
15. Defining the critical gene expression changes associated with expression and suppression of the tumorigenic and metastatic phenotype in Ha-ras-transformed cloned rat embryo fibroblast cells. Su ZZ; Austin VN; Zimmer SG; Fisher PB Oncogene; 1993 May; 8(5):1211-9. PubMed ID: 8479744 [TBL] [Abstract][Full Text] [Related]
16. Up-regulation of lysyl oxidase in spontaneous revertants of H-ras-transformed rat fibroblasts. Hajnal A; Klemenz R; Schäfer R Cancer Res; 1993 Oct; 53(19):4670-5. PubMed ID: 7691400 [TBL] [Abstract][Full Text] [Related]
17. Tumor suppression by IFN regulatory factor-1 is mediated by transcriptional down-regulation of cyclin D1. Kröger A; Stirnweiss A; Pulverer JE; Klages K; Grashoff M; Reimann J; Hauser H Cancer Res; 2007 Apr; 67(7):2972-81. PubMed ID: 17409403 [TBL] [Abstract][Full Text] [Related]
18. Expression of the protein kinase PKR in modulated by IRF-1 and is reduced in 5q- associated leukemias. Beretta L; Gabbay M; Berger R; Hanash SM; Sonenberg N Oncogene; 1996 Apr; 12(7):1593-6. PubMed ID: 8622878 [TBL] [Abstract][Full Text] [Related]
19. Identification and characterization of nucleophosmin/B23/numatrin which binds the anti-oncogenic transcription factor IRF-1 and manifests oncogenic activity. Kondo T; Minamino N; Nagamura-Inoue T; Matsumoto M; Taniguchi T; Tanaka N Oncogene; 1997 Sep; 15(11):1275-81. PubMed ID: 9315094 [TBL] [Abstract][Full Text] [Related]
20. Activation of a cell-cycle-regulated histone gene by the oncogenic transcription factor IRF-2. Vaughan PS; Aziz F; van Wijnen AJ; Wu S; Harada H; Taniguchi T; Soprano KJ; Stein JL; Stein GS Nature; 1995 Sep; 377(6547):362-5. PubMed ID: 7566094 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]